Photo detail

Stories this photo appears in:

Sorrento Therapeutics Sells Cancer Drug and Subsidiary

In a deal potentially worth up to $1.3 billion, San Diego’s Sorrento Therapeutics has sold the rights to its proposed cancer treatment Cynviloq, as well as the wholly owned subsidiary that was developing the drug, to Illinois-based NantPharma.

Tease photo

Sorrento Therapeutics Awarded NIH Grant for Development of Small Molecule Protein Inhibitor

The grant supports research based on biotechnology licensed from The Scripps Research Institute.

Tease photo